|
"hsu jta"的相关文件
显示项目 6-30 / 88 (共4页)
1 2 3 4 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2021-07-30 |
The effects of Abeta1-42 binding to the SARS-CoV-2 spike protein S1 subunit and angiotensin-converting enzyme 2
|
Hsu, JTA;Tien, CF;Yu, GY;Shen, S;Lee, YH;Hsu, PC;Wang, Y;Chao, PK;Tsay, HJ;Shie, FS |
| 國家衛生研究院 |
2020-06-02 |
Zika virus NS3 protease pharmacophore anchor model and drug discovery
|
Pathak, N;Kuo, YP;Chang, TY;Huang, CT;Hung, HC;Hsu, JTA;Yu, GY;Yang, JM |
| 國家衛生研究院 |
2020-05 |
Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors
|
Lin, SY;Chang, CF;Coumar, MS;Chen, PY;Kuo, FM;Chen, CH;Li, MC;Lin, WH;Kuo, PC;Wang, SY;Li, AS;Lin, CY;Yang, CM;Yeh, TK;Song, JS;Hsu, JTA;Hsieh, HP |
| 國家衛生研究院 |
2019-10 |
Inhibition of Rspo-Wnt pathway facilitates checkpoint blockade therapy by anti-RSPO3 antibody (DBPR117)
|
Hsu, JTA;Hung, HC;Chen, CT;Yen, WC;Chang, TY;Chao, PK;Chin-Ting, H;Yen, KJ;Tsai, YR;Chang, CY;Fang, MY;Lai, YL;Shih, JC |
| 國家衛生研究院 |
2018-12 |
Targeting RSPO3 reduces stem cell function in RSPO3-Fusion-positive colon cancer and RSPO3 high lung cancer
|
Hsu, J;Hung, HC;Yen, WC;Chang, TY;Yen, GJ;Huang, CT;Fnag, MY;Lai, YL;Tsai, YR;Chen, CT;Shih, JC;Hsu, JTA |
| 國家衛生研究院 |
2018-10 |
Identification of novel Cdc7 kinase inhibitors as anti-cancer agents that target the interaction with Dbf4 by the fragment complementation and drug repositioning approach
|
Cheng, AN;Lo, YK;Lin, YS;Tang, TK;Hsu, CH;Hsu, JTA;Lee, AYL |
| 國家衛生研究院 |
2018-01 |
Discovery and development of DBPR112 as a clinical candidate: A novel EGFR inhibitor for non-small cell lung cancer
|
Hsieh, HP;Hsu, JTA;Yeh, TK;Chen, CT |
| 國家衛生研究院 |
2017-04 |
Discovery of BPR1K871-a quinazoline based multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation
|
Hsieh, HP;Wang, WC;Shiao, HY;Ke, YY;Lin, WH;Hsu, JTA;Chen, CT;Yeh, TK |
| 國家衛生研究院 |
2016-11-29 |
Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design
|
Chang, CF;Lin, WH;Ke, YY;Lin, YS;Wang, WC;Chen, CH;Kuo, PC;Hsu, JTA;Uang, BJ;Hsieh, HP |
| 國家衛生研究院 |
2016-05-19 |
Non-small-cell lung cancer cells combat epidermal growth factor receptor tyrosine kinase inhibition through immediate adhesion-related responses
|
Wang, HY;Hsu, MK;Wang, KH;Tseng, CP;Chen, FC;Hsu, JTA |
| 國家衛生研究院 |
2015-07 |
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations
|
Chen, CT;Hsu, JTA;Lin, WH;Lu, CT;Yen, SC;Hsu, T;Huang, YL;Song, JS;Chen, CH;Chou, LH;Yen, KJ;Chen, CP;Kuo, PC;Huang, CL;Eugene Liu, H;Chao, YS;Yeh, TK;Jiaang, WT |
| 國家衛生研究院 |
2015-01 |
Identification of ligand efficient, fragment-like hits from an HTS library: Structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity
|
Sarvagalla, S;Singh, VK;Ke, YY;Shiao, HY;Lin, WH;Hsieh, HP;Hsu, JTA;Coumar, MS |
| 國立交通大學 |
2014-12-08T15:39:10Z |
Anti-HCV activities of selective polyunsaturated fatty acids
|
Leu, GZ; Lin, TY; Hsu, JTA |
| 國立交通大學 |
2014-12-08T15:19:20Z |
Anti-HCV activities of selective polyunsaturated fatty acids (vol 318, pg 275, 2004)
|
Leu, GZ; Lin, TY; Hsu, JTA |
| 國立交通大學 |
2014-12-08T15:18:14Z |
Inhibition of hepatitis C virus replication by antimonial compounds
|
Hwang, DR; Lin, RK; Leu, GZ; Lin, TY; Lien, TW; Yu, MC; Yeh, CT; Hsu, JTA |
| 國家衛生研究院 |
2014-12 |
BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus 71
|
Balaji, VA;Chen, GW;Hsieh, PT;Horng, JT;Hsu, JTA;Hsieh, HP;Chen, TC;Weng, KF;Shih, SR |
| 國家衛生研究院 |
2014-11-20 |
The combination effects of LiCl and the active leflunomide metabolite, A771726, on viral-induced interleukin 6 production and EV-A71 replication
|
Hung, HC;Shih, SR;Chang, TY;Fang, MY;Hsu, JTA |
| 國家衛生研究院 |
2014-11 |
Reticulon 3 interacts with NS4B of the hepatitis C virus and negatively regulates viral replication by disrupting NS4B self-interaction
|
Wu, MJ;Ke, PY;Hsu, JTA;Yeh, CT;Horng, JT |
| 國家衛生研究院 |
2014-10 |
Optimization of 5,6-fused pyrimidine-based kinase inhibitors by computer-aided drug design for the treatment of AML
|
Hsu, YC;Shiao, HY;Ke, YY;Hsu, JTA;Lin, WH;Chen, CH;Hsieh, HP |
| 國家衛生研究院 |
2014-05 |
Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach
|
ChangHsu, Y;Ke, YY;Shiao, HY;Lee, CC;Lin, WH;Chen, CH;Yen, KJ;Hsu, JTA;Chang, C;Hsieh, HP |
| 國家衛生研究院 |
2014-05 |
Cover Picture: Facile identification of dual FLT3–aurora a inhibitors: A computer-guided drug design approach (ChemMedChem 5/2014)
|
Chang Hsu, Y;Ke, YY;Shiao, HY;Lee, CC;Lin, WH;Chen, CH;Yen, KJ;Hsu, JTA;Chang, C;Hsieh, HP |
| 國家衛生研究院 |
2014-02 |
Epstein-Barr virus BALF3 has nuclease activity and mediates mature virion production during the lytic cycle
|
Chiu, SH;Wu, MC;Wu, CC;Chen, YC;Lin, SF;Hsu, JTA;Yang, CS;Tsai, CH;Takada, K;Chen, MR;Chen, JY |
| 國家衛生研究院 |
2014-01-08 |
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer
|
Lin, WH;Yeh, TK;Jiaang, WT;Yen, KJ;Chen, CH;Huang, CT;Yen, SC;Hsieh, SY;Chou, LH;Chen, CP;Chiu, CH;Kao, LC;Chao, YS;Chen, CT;Hsu, JTA |
| 國家衛生研究院 |
2013-12 |
Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival
|
Mok, CK;Chen, GW;Shih, KC;Gong, YN;Lin, SJ;Horng, JT;Hsu, JTA;Chen, CJ;Shih, SR |
| 國家衛生研究院 |
2013-09-22 |
A novel Aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment [Erratum:International Journal of Biological Sciences. 2013 Apr 29;9(4):403-411]
|
Shionome, Y;Lin, WH;Shiao, HY;Hsieh, HP;Hsu, JTA;Ouchi, T |
显示项目 6-30 / 88 (共4页)
1 2 3 4 > >>
每页显示[10|25|50]项目
|
